Result: $16.5 million settlement
Year: 2010

Yarrington v. Solvay Pharmaceuticals, Inc.

In March 2010, the Court granted final approval to a $16.5 million settlement of a false advertising class action lawsuit against Solvay Pharmaceuticals. Lieff Cabraser served as Co-Lead Counsel, representing purchasers of Estratest – a hormone replacement drug.

The complaint alleged that Solvay deceptively marketed Estratest as an FDA-approved drug when in fact Estratest was not approved by the FDA. The settlement provided refunds to consumers for up to 30% of the purchase price paid for Estratest. In addition, $8 million of the settlement was allocated to fund programs and activities related to women’s health concerns at medical schools throughout the nation.